Literature DB >> 8328792

Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin.

N Mor1, L Heifets.   

Abstract

A single 2-h pulsed exposure of either human monocyte-derived macrophages or J774 cells infected with Mycobacterium avium to clarithromycin at 3.0 micrograms/ml completely inhibited the intracellular bacterial growth during the first four days of observation, and then only a slight increase in the number of CFU per milliliter took place between the fourth and seventh days. These data suggest that in vivo the intracellular bacteria can be effectively inhibited after a short period when the concentration of the drug in blood reaches its maximum. On the basis of these data, the assumptions that the elimination of bacteremia observed in clarithromycin clinical trials is a result of the activity of the drug not only against bacteria in blood but in macrophages as well and that the peak concentration attainable in blood is essential for these effects can be made.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328792      PMCID: PMC187973          DOI: 10.1128/AAC.37.6.1380

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

3.  Preliminary demonstration of human tuberculoimmunity in vitro.

Authors:  A J Crowle; M May
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

4.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J J Pocidalo; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals.

Authors:  D M Yajko; P S Nassos; C A Sanders; P C Gonzalez; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

6.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages.

Authors:  A J Crowle; N Elkins; M H May
Journal:  Am Rev Respir Dis       Date:  1988-05

Review 8.  The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.

Authors:  N Bahal; M C Nahata
Journal:  Ann Pharmacother       Date:  1992-01       Impact factor: 3.154

Review 9.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

10.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.

Authors:  B Dautzenberg; C Truffot; S Legris; M C Meyohas; H C Berlie; A Mercat; S Chevret; J Grosset
Journal:  Am Rev Respir Dis       Date:  1991-09
View more
  8 in total

1.  The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin.

Authors:  C Fréhel; C Offredo; C de Chastellier
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

2.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

3.  Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium.

Authors:  L Horgen; A Jerome; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

4.  Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium.

Authors:  N Mor; J Vanderkolk; N Mezo; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 5.  Animal and cell-culture models for the study of mycobacterial infections and treatment.

Authors:  I M Orme; A D Roberts; S K Furney; P S Skinner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

6.  Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex.

Authors:  L C Ellis; C A Benson; G I Koenig; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

7.  Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model.

Authors:  S K Furney; P S Skinner; J Farrer; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

8.  Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes.

Authors:  Hitoshi Shimomura; Sena Andachi; Takahiro Aono; Akira Kigure; Yosuke Yamamoto; Atsushi Miyajima; Takashi Hirota; Keiko Imanaka; Toru Majima; Hidenori Masuyama; Koichiro Tatsumi; Takao Aoyama
Journal:  J Pharm Health Care Sci       Date:  2015-11-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.